- Home
- CVKD vs GOVX Comparison
CVKD vs GOVX Comparison
Compare CVKD & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- GOVX
- Stock Information
- Founded
- CVKD 2022
- GOVX 2001
- Country
- CVKD United States
- GOVX United States
- Employees
- CVKD N/A
- GOVX N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- GOVX Health Care
- Exchange
- CVKD Nasdaq
- GOVX Nasdaq
- Market Cap
- CVKD 6.9M
- GOVX 7.0M
- IPO Year
- CVKD 2023
- GOVX N/A
- Fundamental
- Price
- CVKD $12.00
- GOVX $2.07
- Analyst Decision
- CVKD Strong Buy
- GOVX Strong Buy
- Analyst Count
- CVKD 2
- GOVX 4
- Target Price
- CVKD $52.50
- GOVX $14.00
- AVG Volume (30 Days)
- CVKD 44.9K
- GOVX 923.5K
- Earning Date
- CVKD 11-08-2024
- GOVX 11-06-2024
- Dividend Yield
- CVKD N/A
- GOVX N/A
- EPS Growth
- CVKD N/A
- GOVX N/A
- EPS
- CVKD N/A
- GOVX N/A
- Revenue
- CVKD N/A
- GOVX $300,677.00
- Revenue This Year
- CVKD N/A
- GOVX N/A
- Revenue Next Year
- CVKD N/A
- GOVX $565.58
- P/E Ratio
- CVKD N/A
- GOVX N/A
- Revenue Growth
- CVKD N/A
- GOVX N/A
- 52 Week Low
- CVKD $5.40
- GOVX $1.09
- 52 Week High
- CVKD $32.55
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- CVKD 55.95
- GOVX 33.45
- Support Level
- CVKD $11.00
- GOVX $2.40
- Resistance Level
- CVKD $15.37
- GOVX $3.17
- Average True Range (ATR)
- CVKD 1.43
- GOVX 0.24
- MACD
- CVKD -0.16
- GOVX -0.05
- Stochastic Oscillator
- CVKD 37.26
- GOVX 5.99
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.